Radimmune Therapeutics
Developing novel therapies for cancer
About Radimmune Therapeutics
Radimmune Therapeutics, founded in 2015 by Paresh Ghelani, is a biotechnology firm focused on developing novel treatments for cancer. The company is headquartered in Menlo Park, California, and operates within the biopharmaceutical market, specializing in radioimmunotherapy (RIT). Its business model centers on the research and development of a proprietary technology platform to create new cancer therapies. Radimmune secured $13.6 million in a Series A funding round in August 2019.
The company's core product is a form of molecular targeted radiotherapy that employs monoclonal antibodies (mAbs) chemically linked to a radionuclide. This therapeutic agent is infused and designed to target a specific antigen within the cancer cell microenvironment, such as in melanoma. By binding to the target antigen, the treatment delivers focused radiation directly to tumor cells, which helps to minimize the toxic effects on surrounding healthy tissues. Radimmune is particularly focused on Alpha Emitting RIT, which uses alpha-emitting radionuclides linked to customized mAbs. This method is considered potent due to the high relative biologic effectiveness of alpha rays, which also have a very short path length in tissue, allowing for precision in targeting cancer cells.
The scientific founders, Ekaterina Dadachova and David Rickles, along with a team of advisors, provide strategic guidance for the company's research initiatives. In a significant step towards clinical trials, Radimmune partnered with Goodwin Biotechnology in late 2018 to manufacture its lead therapeutic candidate for a Phase I study in melanoma treatment. The company received a Small Business Innovation Research (SBIR) grant from the National Institutes of Health/National Cancer Institute (NIH/NCI) based on its preclinical results.
Source: Dealroom company dataNews
Open roles
Radimmune Therapeutics in the Burlingame ecosystem
The Radimmune Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Radimmune Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Radimmune Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.